vorinostat has been researched along with Abnormalities, Drug-Induced in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animals were dosed on Gestation Days 6-20 or 7-20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively." | 1.34 | Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. ( Kerr, JS; Turner, KJ; Wise, LD, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, LD | 1 |
| Turner, KJ | 1 |
| Kerr, JS | 1 |
| Giavini, E | 1 |
2 other studies available for vorinostat and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Dose-Response Relationship, Drug; Enzyme Inhibito | 2007 |
Comment on developmental toxicity evaluation on Vorinostat and relationship with HDAC inhibition.
Topics: Abnormalities, Drug-Induced; Animals; Bone Development; Enzyme Inhibitors; Female; Fetal Development | 2007 |